Udayavni Special

Antibiotics may help treat common form of dementia: Study

Team Udayavani, Jan 11, 2020, 4:16 PM IST

Washington: Researchers have found that a class of antibiotics called ‘aminoglycosides’ may be a promising treatment for a form of early onset dementia, an advance that may lead to new clinical strategies against the memory decline syndrome.

According to the study, published in the journal Human Molecular Genetics, frontotemporal dementia, the most common type of the syndrome, begins between ages 40 and 65, and affects the frontal and temporal lobes of the brain.

The syndrome leads to behaviour changes, difficulty in speaking, writing, and memory deterioration, the researchers, including those from the University of Kentucky in the US, said.

Some patients with this form of dementia have a specific genetic mutation which prevents their brain’s cells from making a protein called progranulin, the scientists said in a statement.

While the protein is not thoroughly studied, researchers believe that its absence is linked to this form of dementia.

In the current study, scientists discovered that after aminoglycoside antibiotics were added to nerve cells exhibiting this mutation, the cells started making full-length progranulin protein by skipping the mutation.

“These patients’ brain cells have a mutation that prevents progranulin from being made. The team found that by adding a small antibiotic molecule to the cells, they could ‘trick’ the cellular machinery into making it,” said Matthew Gentry, a co-author of the study from the University of Kentucky.

Two aminoglycoside antibiotics – Gentamicin and G418 – were both effective in fixing the mutation, and making the functional progranulin protein, the study noted.

According to the researchers, adding Gentamicin or G418 molecules to the affected cells, caused them to produce the protein at levels of up to 50 to 60 per cent as produced by normal cells without the mutation.

The scientists plan to study the antibiotics’ effects on mice carrying the mutation which causes frontotemporal dementia.

While Gentamicin is a clinically approved medicine, the researchers said its usage is limited since it is associated with a number of adverse side effects.

“If we can get the right resources and physician to work with, we could potentially repurpose this drug. This is an early stage of the study, but it provides an important proof of concept that these aminoglycoside antibiotics or their derivatives can be a therapeutic avenue for frontotemporal dementia,” said study co-author Haining Zhu from the University of Kentucky.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Don’t vote for JD(S): Siddaramaiah to minority community

Opposition flays Kerala govt’s flood management

Pakistan Navy claims it blocked Indian submarine from entering into country’s waters

K’taka: Six achievers chosen for Sri Maharishi Valmiki Awards 2021

PM Modi afraid of speaking on China: Owaisi

Maharashtra: Theatres to reopen from October 22; restaurants, eateries can function till midnight

IndiGo cautions candidates against fake job offers

Related Articles More

Global Hunger Index 2021 reflects India’s reality where hunger accentuated post Covid: Oxfam

AstraZeneca joins hands with RGCI to treat leukaemia patients

Continued coordinated policy response to combat COVID-19 is critical to overcome health crisis: IMF

Mixing vaccines highly effective against Covid-19: Lancet study

People want to use bleach and antiseptic for COVID and are calling us for advice




Specialties Of Kapila MalnadGidda cow Breed


Chintamani Crime news

Latest Additions

Man’s kidney removed during stone operation; Hosp ordered to pay Rs 11.23 lakh compensation

Increasing activities by China in depth areas of eastern sector: Eastern Army Commander

Don’t vote for JD(S): Siddaramaiah to minority community

Opposition flays Kerala govt’s flood management

Over 300 people rescued from flood-affected Uttarakhand: NDRF

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.